Concerns about higher rates of suicide-related adverse event reports in depressed children and adolescents taking selective serotonin reuptake inhibitors compared with placebo in RCTs have prompted regulatory bodies in the United States, the United Kingdom, and Europe to issue warnings urging clinicians to monitor suicide risk and adverse effects carefully when prescribing antidepressants to youth. Such concerns need to be weighed against the risk of untreated depression because suicide is the third leading cause of death in youth and more than 90% of suicides in depressed youth are untreated at the time of death.130